Provided is a use of an attenuated gene engineering Salmonella typhimurium strain VPN 20009-M in the preparation of medicaments for preventing and treating cancer metastasis.

A method for fabricating silicon nanowires. The method includes the steps of: depositing a silicon nitride layer on a silicon on insulator (SOI) starting wafer; patterning the silicon nitride to define at least one silicon microbar; etching the SOI starting wafer to expose the at least one silicon microbar, wherein the at least one microbar is surrounded by a raised perimeter; growing a silicon oxide layer on the raised perimeter of the at least one microbar; and etching a portion of the at least one silicon microbar to produce at least one silicon nanowire adjacent the silicon oxide layer.

The development of attenuated live vaccines against salmonellosis has increased over the past years due to the nonexistence of completely effective vaccine formulations which enable different S. enterica serovars to be more effectively controlled. The development of a safe strain that is capable of inducing an efficient immune response involves the production of various attenuated mutants that can be clinically tested or which have unique features that can be combined with other specific mutations, generating increasingly safe and efficient strains. The present invention relates to a vaccine vector comprising mutants for thegene fis, wherein the protein that results from expression thereof, Fis, associates with the bacterial nucleoid regulating the expression of various genes, many of which are related to bacterial pathogenicity. The present invention also relates to a vaccine comprising said mutant strains which generate a response capable of inducing efficient protection against salmonellosis.

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.

The invention relates to a conjugate based on Vi polysaccharide which is fragmented and a carrier protein, to compositions comprising said conjugate and to methods for making said conjugates and compositions.

The invention relates to a polyvalent, combined immunising and/or therapeutic preparation for use in bacterial infections and food poisoning, particularly salmonellosis, comprising inactivated Salmonella sp. strain with antibodies bound thereto, characterized in that the said antibodies are selected so as to bind to the antigenic epitopes in structures of repeating O- specific units in the basic groups of Salmonella bacteria, which are responsible for the principle of reaction with the host immune system, while not blocking the epitopes responsible for the recognition of Salmonella serotype, wherein the inactivated bacteria are bacteria of the Salmonella genus enterica species, subspecies: enterica, salamae, arizonae and/or diarizonae, houtenae, Indica. The invention relates also to a method for production of this polyvalent, combined immunising and/or therapeutic preparation and a vaccine against salmonelloses comprising said preparation.

The present invention relates to a drug-delivery carrier composition characterized by comprising a bacterium of the genus Corynebacterium and minicells derived from the bacterium of the genus Corynebacterium; the invention having the advantage of being relatively safer to use in the human body than other bacteria (e.g. E. coli, bacteria of the genus Salmonella and bacteria of the genus Bacillus) or than drug-delivery carriers derived from other bacteria. When the present invention comprises an anticancer drug protein expression construct (e.g. a protein expression recombinant vector), the invention provides a targeting technique via anticancer drug protein overexpression , effective in vivo protein expression regulation and target factor expression. Also, the present invention makes it possible to deliver a drug into the body in a stable fashion, and therefore makes it possible to maximise anticancer therapy effects.

The invention relates to the use of an agent selected from the group consisting of antibodies, antibody portions, insulin-like growth factor antagonists, toll-like receptor antagonists, and mixtures thereof for the treatment or the prophylaxis of certain diseases.

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100 %. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

A method for fabricating silicon nanowires. The method includes the steps of: depositing a silicon nitride layer on a silicon on insulator (SOI) starting wafer; patterning the silicon nitride to define at least one silicon microbar; etching the SOI starting wafer to expose the at least one silicon microbar, wherein the at least one microbar is surrounded by a raised perimeter; growing a silicon oxide layer on the raised perimeter of the at least one microbar; and etching a portion of the at least one silicon microbar to produce at least one silicon nanowire adjacent the silicon oxide layer.

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

A portable system for real time detection of the presence of an infectious agent in a biological sample employs a reagent which detects the presence of a specific infectious agent in the sample, and emits a detectable signal when the reagent reacts with the sample and detects the presence of the infectious agent. A test cartridge has a reaction chamber for receiving the sample and the reagent. The reaction chamber has a predetermined internal geometry and at least one inner surface. Introducing the sample and the reagent into the test cartridge mixes the sample and the reagent. A testing unit receives the test cartridge, and includes a sensor for detecting an emitted detectable signal. The detection of the emitted detectable signal is indicative of the presence of the infectious agent in the sample.

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.

The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.

The present invention relates to a method of reducing the concentration of Gram-negative bacteria in a food product, the method comprising adding a red wine extract produced from red wine by dealcoholization, concentration and drying, and a culture comprising at least one class IIa bacteriocin-producing lactic acid bacterial strain to a food product, ripening the food product, and storing the food product at a temperature of at the most 15 ̊C until a concentration less than 1 E-1 of Gram-negative bacteria. In a preferred embodiment of the invention, Gram-negative bacteria already present are eliminated. In one embodiment of the invention, the Gram-negative bacteria are Salmonella ssp.. The bacteriocin-producing culture may comprise at least one of Lactobacillus curvatus (DSM 18775) and Pediococcus acidilactici (DSM 28307). The invention further relates to a kit for reducing the concentration of Gram-negative bacteria in a food product comprising a red wine extract produced from red wine by dealcoholization, concentration and drying, and a culture comprising at least one class IIa bacteriocin-producing lactic acid bacterial strain.

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

本发明公开了种伤寒糖蛋白的生物制备方法及其应用。本发明公开种细菌多糖修饰的蛋白的制备方法，包括将脑膜炎奈瑟球菌O-寡糖转移酶PglL的底物蛋白与脑膜炎奈瑟球菌O-寡糖转移酶PglL在O-抗原连接酶基因缺陷的细菌中共表达，得到细菌多糖修饰的蛋白。本发明在提高疫苗的均性，提高疫苗的生产效率，降低成本，具有广泛的应用前景，可用于预防伤寒病原菌引起的疾病。

The invention provides non-coding RNA (ribonucleic acid) of salmonella as well as identification and application of the non-coding RNA. Specifically, tests of the invention show that the salmonella presents the non-coding RNA (ncRNA) of the salmonella into a host cell to produce milRNA similar to microRNA by making use of a microRNA shear system of the cell, and the milRNA is used for regulating and controlling the immune system so as to protect the salmonella from being eliminated by a host. An inhibitor of the milRNA is used for adsorbing the milRNA to ensure that the survival ability of bacteria in cells can be effectively inhibited and the viability of the bacteria is reduced. The invention also provides a related reagent and method for effectively detecting, treating and researching the salmonella or infectious diseases.

The present invention relates to predicting the risk of developing hypertriglyceridemia in a subject by quantitating the amount of enterobacteria, e.g., E. coli, in the subject's gastrointestinal system. The invention also relates to treating a subject with hypertriglyceridemia or at risk of having the condition.

Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).

A vaccine composition for birds comprising as an active ingredient a structure containing 0-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing 0-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole -cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

In alternative embodiments, the invention provides high throughput, multiplexed systems or methods for detecting a biological, a physiological or a pathological maker, or a single molecule or a single cell using a droplet microfluidics system integrated with use of a sensor or a sensing system, an aptamer, or a DNAzyme. In alternative embodiments, the sensor or sensing system comprises a nucleic acid based, an antibody based, an enzyme based or a chemical based sensor or sensing system. In alternative embodiments, the invention provides methods for detecting a biological, a physiological or a pathological marker, or a single molecule or a single cell using a droplet system integrated with rapid and sensitive fluorescence detection systems including, for example, a 3D Particle Detector. In alternative embodiments, the invention provides systems comprising Integrated Comprehensive Droplet Digital Detection (IC 3D).

Resumen de: KR20160092579A

본 발명은 살모넬라 티피뮤리움 KCCM 11806에 특이적으로 결합하는 다중인식 펩타이드 고분자 프로브에 관한 것이다. 본 발명의 고분자 프로브를 이용하면 살모넬라 티피뮤리움 KCCM 11806을 효과적이고 특이적으로 검출할 수 있다.